Table 5.
Protocols to produce induced pluripotent stem cell-derived mesenchymal stem cells by approaches that use Platelet Lysate
Ref.
|
iPSC origin
|
iPSC to iMSC protocol
|
Time
|
Application
|
Citations
|
Frobel et al[71], 2014 | BM-MSCs | (1) EB formation on ultra-low attachment plates; and (2) Cells cultured with standard medium for MSC: DMEM + L-Glutamine + p/s + hPL + heparin on matrigel-coated wells then passaged on gelatin-coated wells | 35 | Epigenetic study of iMSC | 116 |
Luzzani et al[72], 2015 | Foreskin fibroblasts | (1) iPSC cultured in matrigel/geltrex-coated dishes with a-MEM + 10% PL + p/s + B7 or DMEM + 10% FBS; and (2) Cells cultured with no-coated dishes | 20 | MSC differentiation using platelet lysate | 26 |
McGrath et al[54], 20191 | Dermal fibroblasts | (1) iPSC-MP thawed and expanded in KO DMEM + bFGF + L-Glutamine + MEM NEAA + FBS (20%) + Antibiotic-Antimycotic+ β-ME; and (2) Cell are plated on gelatin coated-plates with DMEM KO + heparin + hPL+ bFGF + L-Glutamine + MEM NEAA + Antibiotic-Antimycotic+ β-ME | NA | iMSC differentiation: GMP-compatible and xeno-free cultivation | 6 |
iPSC origin refers to the cell type used for reprograming; Time is indicated as the minimum number of days required to obtain iMSCs; Citations show numbers on March 2020.
In references indicate the study includes methods in more than one protocol category. bFGF: Basic fibroblast growth factor; BM: Bone marrow; β-ME: β-Mercaptoethanol; EB: Embryoid body; DMEM: Dulbecco's modified Eagle's medium; FBS: Fetal bovine serum; GMP: Good manufacturing procedures; hPL: human platelet lysate; hEGF: Human epidermal growth factor; iMSCs: Induced pluripotent stem cell-derived mesenchymal stem cells; iPSC: Induced pluripotent stem cell; KO DMEM: Knockout Dulbecco's modified Eagle's medium; α-MEM: Minimum essential medium Eagle; MSC: Mesenchymal stem cell; NA: Not available; NEAA: Non-essential amino acid; p/s: Penicillin-streptomycin.